Veracyte (VCYT) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $115.9 million, up 29% year-over-year, driven by 34% testing revenue growth and strong execution in Decipher and Afirma, with total test volume up to 39,032.

• Net income for Q3 2024 was $15.2 million, a significant improvement from the prior year, and adjusted EBITDA was $27.3 million (24% of revenue).

• Cash and equivalents at quarter-end were $274.1 million, with $38 million generated in Q3 and strong operational cash flow.

• The C2i Genomics acquisition in February 2024 expanded MRD detection capabilities and added $56 million in goodwill.

• Strategic focus remains on expanding Decipher and Afirma, launching IVD and MRD products, and international growth, with new leadership appointments.

Financial highlights

• Total Q3 revenue: $115.9 million (+29% YoY); testing revenue: $109.5 million (+34% YoY); product revenue: $3.2 million (-21% YoY); biopharma/other revenue: $3.1 million (-23% YoY).

• Non-GAAP gross margin: 71% (up YoY); GAAP gross margin: 68%.

• Adjusted EBITDA: $27.3 million (24% margin); non-GAAP net income: $25.99 million; diluted EPS: $0.19; non-GAAP diluted EPS: $0.33.

• Cash, cash equivalents, and short-term investments at quarter-end: $274.1 million.

• Cash from operations for the nine months ended September 30, 2024: $50.6 million.

Outlook and guidance

• 2024 total revenue guidance raised to $442–$445 million (22–23% YoY growth), with testing revenue growth expected at ~28%.

• Year-end 2024 cash expected at $280–$285 million, including $10–$15 million in milestone payments and capex.

• Full-year 2024 Adjusted EBITDA margin expected to exceed 20%.

• Afirma projected to grow at high single digits in 2025; Decipher growth to be driven by metastatic indication ramping in late 2025.

• Continued investment in MRD and IVD test development and international expansion.